Adrian Johnson

TLDR: Venture capitalists invested nearly $3.2 billion in the crypto sector in Q2 of 2024, according to Galaxy Digital. Deal count slightly decreased from Q1, but capital invested rose, indicating significant competition

TLDR: HepaRegeniX, a German company, raised €15M in Series C funding for their regenerative therapy for liver diseases. The funding was led by Vesalius Biocapital IV with participation from existing investors. HepaRegeniX,

TLDR: North Sky Capital raises $250 million for impact fund focused on energy transition, climate tech, circular economy, and healthy living sectors CG VI fund is an EU Sustainable Finance Disclosure Regulation

TLDR: Flagship Pioneering raises $3.6 billion for biotech fund, focusing on AI. Strategic partnerships with Pfizer, Samsung, Thermo Fisher Scientific, and Novo Nordisk Flagship Pioneering, a venture capital group, has closed a

TLDR: Index Ventures raises $2 billion for AI projects, with $800 million earmarked for early-stage startups. The firm sees AI as a technological “platform shift” and has invested in various AI startups,

TLDR: Flagship Pioneering raises $3.6 billion for AI-driven biotech ventures Funds will be used to launch new biotech companies utilizing artificial intelligence for drug discovery In a recent development, Flagship Pioneering has

TLDR: Swell VC is an early-stage venture capital firm focused on market-defining opportunities. Co-founder Rusty Ralston emphasizes the importance of people in startup success. Swell VC: An Interview With Co-Founder Rusty Ralston

TLDR: Flagship Pioneering, a biotech investment firm, raises $3.6 billion in new funding. The funds include $2.6 billion for Flagship Pioneering Fund VIII and $1 billion for side funds and strategic partnerships.

TLDR: Flagship Pioneering has raised $2.6 billion through its eighth venture fund, with an additional $1 billion coming from side funds. The firm aims to form more partnerships with Big Pharma companies,

TLDR: Corporations need to embrace “fast, cheap, and weird” experiments to survive in today’s fast-paced world. Parker argues that companies must focus on resilience rather than efficiency to weather crises and foster